
David Sinclair injects first glaucoma patient as “reprogramming” races toward rejuvenation
Life Biosciences has dosed its first volunteer with an intra-eye treatment, betting cell reprogramming can regenerate more than vision.

Curating from trusted global sources…
Curated from trusted global sources, refined into briefing-grade analysis with executive summaries, insights, and bullet-point takeaways.

Life Biosciences has dosed its first volunteer with an intra-eye treatment, betting cell reprogramming can regenerate more than vision.

Week ending June 6: $3.64bn in SR13.67bn transactions, with construction and education powering gains despite a value dip.

A HK$562.6m mansion deal puts a Singapore-linked buyer beside Richard Li and Pony Ma in Hong Kong’s elite enclave.

Meta’s CEO argues a small team can move AI fast, while compute limits and talent competition reshape how labs bet.

Prediction markets turned into relegation insurance drama, and Spain’s regulators are now watching Kalshi and Polymarket closely.

In a Masters of Scale interview, Rivian’s CEO lays out two reasons the R2 stands apart from Tesla.

The $30M round backs an AI call-answering assistant, led by Prosus Ventures and Tomales Bay Capital.

The world’s largest online betting company is pulling its London shares, forcing UK-market watchers to reassess what “liquidity” costs.

Economists use AT&T’s iPhone monopoly to argue smartphone time may crowd out connection, not just economics.

If SpaceX lands its record-breaking IPO math, it redraws the entire playbook for mega-IPOs, talent wealth, and capital markets.

A Schengen-style GCC rollout promises less red tape, but eligibility, insurance, and pilot restrictions still matter.

A Vinnytsia rehab effort turned into a business for Ukraine’s blind veterans, built on touch, flow, and income.